Please ensure Javascript is enabled for purposes of website accessibility

Where Will Moderna Be in 1 Year?

By Sushree Mohanty – Sep 2, 2020 at 8:09AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This biotech has gained a lot of traction with its coronavirus vaccine candidate this year, but will the momentum continue?

All eyes are on drug manufacturers in 2020 as they race to develop the first coronavirus vaccine. Globally, recorded cases of COVID-19 have surpassed 25 million, with at least 847,000 related deaths worldwide. More than 6 million cases have been reported in the U.S. alone, with at least 183,000 deaths as of Aug. 30.

According to the World Health Organization, there are more than 150 novel coronavirus vaccine candidates in development now, with nearly 30 of them in clinical testing. U.S.-based Moderna (MRNA -0.23%) reported positive results from the phase 1 trial for its COVID-19 mRNA vaccine in July, and started the phase 3 trial on July 27. It's no surprise that its stock is up 245% year to date, while the S&P 500 has risen just 9%.

But what will happen to Moderna if its late-stage trials aren't successful, or if regulatory approvals for its potential vaccine pose some challenge? Even if it is successful, what does the next year look like for the company?

MRNA Chart

MRNA data by YCharts

Moderna's vaccine candidate progress

Moderna's vaccine candidate, mRNA-1273, got a boost in April after it received $483 million in funding from the Biomedical Advanced Research and Development Authority. The urgency of ending the pandemic has led governments to expedite the vaccine development process, which usually takes many years. Moderna recently received an additional $472 million through Operation Warp Speed (OWS, a Trump administration initiative) to support its late-stage trials.

The phase 3 trial for mRNA-1273 will test it at a dosage of 100 micrograms on 30,000 participants to see whether "primary endpoints of prevention of symptomatic COVID-19 disease are achieved in the vaccine-treated group." The phase 1 results published in the New England Journal of Medicine revealed the vaccine dosage was safe, and the phase 2 study is under way.

Moderna is scaling up to produce 500 million to 1 billion doses a year beginning in 2021, with Lonza Group as its production partner. On Aug. 28, management announced that Moderna is in talks to sell 40 million or more doses of its potential vaccine to Japan's Ministry of Health, Labour and Welfare, starting in the first half of 2021. It says it is also in "advanced discussions" with the European Commission to supply Europe with 80 million doses.

Before this, the U.S. government had already pledged more than $1.5 billion for 100 million doses of Moderna's potential vaccine, with the option to buy up to an additional 400 million doses under OWS.

A gloved hand holds up a glass vial labeled "Coronavirus"

Image source: Getty Images.

What will Moderna look like a year from now?

Moderna's outlook a year from now is highly dependent on how its vaccine candidate fares in late-stage testing.

Management plans to price their potential vaccine at between $32 to $37 per dose for the smaller orders. It has, however, offered a discount to the U.S. government to provide the initial 100 million doses at $15 each -- and why not? The largest funding for its vaccine candidate has come from the U.S. government, after all.

If its vaccine candidate is successful, it could garner huge revenue for Moderna. However, once the pandemic ends, and if the coronavirus does not return, demand for the vaccine could ultimately decline. Transportation and storage of the potential vaccine, which needs to be kept very cold, could also prove unfavorable for the company if competitors make a vaccine that is easier to transport and store.

Keep in mind that in the vaccine development process, many things can go wrong. Vaccines can fail late-stage trials and encounter issues with regulatory approval, and it's always possible that another drugmaker will come out with a successful vaccine first. 

Given all that, it's especially important to note that Moderna doesn't have any other approved products on the market. Currently, its other drug candidates are either in phase 1 or 2 trials, or the pre-clinical testing stage. As of Aug. 5, the company said it has "23 mRNA development candidates in its portfolio with 13 in clinical studies."

For now, Moderna is still unprofitable, but its cash position remains robust. As of June 30, it had $3.1 billion in cash, cash equivalents, and investments. 

Is Moderna a good investment for the future?

Moderna has tough competition in this race -- SinopharmSinovac Biotech, Pfizer, AstraZeneca, and BioNTech have some of the more advanced candidates -- but its already soaring shares could skyrocket if its vaccine is approved. Shares of Moderna have gained 245% so far this year, while AstraZeneca and BioNTech are up 12% and 89% and Pfizer has declined by 3.2%.

AZN Chart

AZN data by YCharts

Even if another company surpasses Moderna in the vaccine race, the company can still profit from the other drugs in its pipeline -- but it could be years before they bring in revenue. That makes Moderna a good biotech stock for aggressive investors who believe better rewards come with greater risk.

Sushree Mohanty has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$176.40 (-0.23%) $0.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.